Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26011545 | 0.85 | CACNA1H (0.38) | CACNA1HHTR2AHTR2CCRHR1 | |
| SCHEMBL24008096 | 0.75 | ACHE (0.39) | CACNA1HHTR2AHTR2CCRHR1 | |
| SCHEMBL24007023 | 0.74 | HTR2A (0.41) | CACNA1HHTR2AHTR2CCRHR1 | |
| SCHEMBL25747210 | 0.72 | HTR2A (0.36) | CACNA1HHTR2AHTR2CCRHR1 | |
| SCHEMBL25745865 | 0.71 | HTR2A (0.37) | HTR2AHTR2CCRHR1 | |
| SCHEMBL25746004 | 0.70 | AR (0.39) | HTR2AHTR2C | |
| SCHEMBL25745999 | 0.69 | HTT (0.42) | — | |
| SCHEMBL24007020 | 0.68 | HTR2A (0.33) | HTR2AHTR2C | |
| SCHEMBL26032718 | 0.61 | ALDH1A1 (0.50) | — | |
| SCHEMBL16009749 | 0.61 | HTR2A (0.39) | HTR2AHTR2CCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CACNA1H 4573/4885HTR2A 1660/4885HTR2C 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.